Will Merck and Moderna announce a U.S. FDA submission for intismeran autogene in melanoma before December 31, 2026?

Question

This market resolves YES if Merck & Co., Inc. and/or Moderna, Inc. publicly announce, on or before December 30, 2026 at 11:59 PM Central European Time, that a formal U.S. regulatory application seeking FDA approval for intismeran autogene (V940 / mRNA-4157), in combination with KEYTRUDA (pembrolizumab), for the adjuvant treatment of resected melanoma has been submitted to the United States Food and Drug Administration.

A qualifying submission may be described by the companies or FDA as a:

Biol

Problyx · Accepted Answer

Yes — the community forecast puts this at 72%.

Problyx · Answer

No — the community forecast puts this at 28%.